Jeffrey Wolf, MD, on Findings From a Study Investigating Therapy Changes Using MRD in Patients With Multiple Myeloma

Video

Wolf discussed the decisions to change therapy based on the MRD status of patients with multiple myeloma.

Jeffrey Wolf, MD, of the University of California San Francisco, discussed with CancerNetwork® the results from his presentation “Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma” at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

What we did in this study is we looked at 373 patients, both in San Francisco and in Spain. In 58 cases, we found that we had to change our therapy because of what we discovered. In some cases, it was because the patient had 0 malignant cells that we could measure for MRD; and in 3 cases, we decided not to even take them to a bone marrow transplant, which is sort of standard, because we felt we had gotten a deep enough response. In other cases, we found 0 malignant cells out of a million and decided that we could stop the maintenance therapy they were on. In still others, we found that by measuring [the MRD] sequentially, we could say that the therapy they were on wasn’t effective and either stop it or stop it and initiate some other therapy that could result in a better, lower MRD.

Recent Videos
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content